In8Bio (INAB) Cash & Equivalents (2020 - 2026)

In8Bio has reported Cash & Equivalents for 7 years, with the latest figure at $21.9 million in Q1 2026.

• Quarterly Cash & Equivalents rose 84.56% year-over-year to $21.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.9 million (up 84.56% YoY) and the FY2025 annual result came in at $27.1 million, up 137.94% from the prior year.
• Cash & Equivalents retreated to $21.9 million in Q1 2026 per INAB's latest filing, from $27.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $32.4 million in Q1 2022 and troughed at $4.3 million in Q3 2024.
• A 5-year average of $17.1 million and a median of $13.5 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 66.86% in 2024, then soared 150.92% in 2025.
• Over 5 years, Cash & Equivalents stood at $18.4 million in 2022, then advanced by 16.84% to $21.5 million in 2023, then plunged by 47.14% to $11.4 million in 2024, then jumped by 137.94% to $27.1 million in 2025, then slipped by 19.01% to $21.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $21.9 million, $27.1 million, and $10.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.